19/01/2026
Global Milestone in Cell Therapy!
Shenzhen Celconta Life Science Co.Ltd’s PANK Cell Therapy (allogeneic NK cell therapy derived from PBMC) has been granted FDA Orphan Drug Designation (ODD) for Hepatocellular Carcinoma (HCC) – a first-of-its-kind recognition for NK cell therapies targeting HCC worldwide!
This designation from the U.S. FDA validates the innovative potential of our proprietary cell therapy in treating liver cancer, and will accelerate our global R&D, clinical trials, and market access efforts.
Proud to lead the advancement of cellular therapeutics for rare and life-threatening diseases!